Researchers are exploring the use of B cell targeted CAR-T therapy as a potential treatment for autoimmune diseases. Clinical trials are underway, with some reporting data on remissions and relapses in severe refractory cases, and companies such as Tempest Therapeutics and Fate Therapeutics advancing their CAR-T candidates into planned trials. Some studies have also reported instances of lasting remission in patients with severe autoimmune diseases treated with CAR-T therapy.